Myasthenia gravis in children: analysis of 18 patients

Area of Science:

• Pediatric Neurology
• Autoimmune Disorders
• Neuromuscular Diseases

Background:

• Childhood myasthenia gravis (MG) is a rare autoimmune disorder affecting neuromuscular junctions.
• It comprises a small percentage of all myasthenia gravis cases.
• Early diagnosis and individualized treatment are crucial for managing pediatric MG.

Purpose of the Study:

• To analyze the clinical characteristics, diagnostic methods, and treatment outcomes of pediatric myasthenia gravis patients.
• To evaluate the efficacy of various therapeutic interventions, including pyridostigmine, steroids, thymectomy, and immunosuppressants.
• To emphasize the need for personalized treatment strategies in childhood MG.

Main Methods:

• Retrospective study of 18 pediatric patients diagnosed with myasthenia gravis.
• Data collection included clinical presentation, age of onset, disease severity, myasthenic crises, diagnostic tests (EMG, chest CT, antibody testing), and treatment responses.
• Analysis of outcomes following pyridostigmine, prednisone, thymectomy, intravenous immunoglobulin, and azathioprine.

Main Results:

• Most patients presented with moderate to severe generalized disease, and a significant portion experienced myasthenic crises.
• Electromyography (EMG) and acetylcholine receptor antibody testing showed variable diagnostic utility.
• Many patients required escalation of therapy beyond pyridostigmine, with thymectomy and immunosuppressants showing variable but sometimes significant benefits.

Conclusions:

• Pediatric myasthenia gravis often presents with severe symptoms and may necessitate aggressive, multi-faceted treatment approaches.
• Standard treatments like pyridostigmine may be insufficient for many children.
• Individualized treatment plans, potentially including thymectomy and immunosuppressive therapies, are essential for optimal outcomes in childhood MG.